Thank you for registering your account
Thanks for joining touchENDOCRINOLOGY to hear about news and updates from across the Endocrinology community.
We’ve sent you an email to verify your email address. Please click on the link to confirm your account.
You can review your email preferences at any time or update your account details
Continuing the conversation in growth hormone disorders – how do we progress towards personalized medicine for patients with acromegaly?
Stay up to date with the latest developments in the diagnosis, management and treatment of patients with acromegaly with our expert summary from the European Congress of Endocrinology (ECE) in Lyon, France, 18–21 May 2019. Part 1: Watch internationally renowned expert Prof. John Wass review key data from ECE2019 Part 2: Choose from leading experts who discuss what the data findings mean for global and regional practice
- Interpret the latest information and guidance about the need for early diagnosis and monitoring of acromegaly
- Recall the most recent data around patient and disease characteristics, including the importance of recognizing comorbidities, in order to select the optimal treatment strategy for each individual patient with acromegaly
- Recognize the role of medical treatment options for acromegaly and best practice for patient management using a multidisciplinary team approach
How can the selection of patients with type 1 diabetes suitable for adjunctive treatment with SGLT inhibitors be optimized?
Watch two experts discuss the use of sodium-glucose co-transporter (SGLT) inhibitors as an adjunct to insulin in patients with type 1 diabetes (T1D). Manon Khazrai, Dietitian and Diabetes Counsellor, considers why there is a need for adjunctive therapy and why SGLT inhibitors are a suitable option. Debbie Hicks, Nurse Consultant – Diabetes, provides insight into patient selection and mitigating the risk of diabetic ketoacidosis.
- Describe the rationale for using sodium-glucose co-transporter (SGLT) inhibitors as an adjunct to insulin therapy in patients with type 1 diabetes (T1D)
- Recognize patients with T1D who are suitable for treatment with an SGLT inhibitor as an adjunct to insulin therapy
- Describe the risk factors for and key signs and symptoms of diabetic ketoacidosis (DKA), especially euglycemic DKA
Christopher Cannon, ADA 2020: Results of the Phase III VERTIS-CV Trial
It was a pleasure to speak to Christopher Cannon to discuss the much-anticipated results of the VERTIS-CV trial (ClinicalTrials.gov Identifier: NCT01986881) evaluating the efficacy and safety and cardiovascular outcomes of ertugliflozin in type 2 diabetes. Questions 1. Could you tell us a little about the VERTIS-CV trial and its primary and secondary outcome data? (0:06) […]
Stefano Del Prato, EASD 2020 – Planning a virtual meeting
We were delighted to speak with EASD President Prof. Stefano Del Prato (University of Pisa and University Hospital of Pisa) ahead of this year’s virtual meeting to hear how the meeting has been adapted to a virtual format. Questions 1. How did you go about planning for virtual EASD?(00:05) 2. What key features are you […]
Stefano Del Prato, EASD 2020 – What to look out for at this year’s meeting
We caught up with EASD President Prof. Stefano Del Prato (University of Pisa and University Hospital of Pisa) ahead of this year’s virtual meeting to hear about the key topics being discussed. Disclosures: Prof. Del Prato has received research support from AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme and served on the advisory board for […]
Acromegaly Due to McCune–Albright Syndrome
US Endocrinology. 2020;16(1):47–50 DOI: https://doi.org/10.17925/USE.2020.16.1.47
McCune–Albright syndrome (MAS) is a genetic disorder first described by McCune1 and Albright2 in the 1930s as a triad of polyostotic fibrous dysplasia, café-au-lait spots, and precocious puberty (Figure 1). Since then, other hyperfunctioning endocrinopathies have been described in MAS, including hyperthyroidism, Cushing’s syndrome, hypophosphatemic osteomalacia, and acromegaly.3 Patients with MAS display mosaicism as the disease results […]
Pheochromocytoma Due to TMEM127 Mutation – The Importance of Genetic Testing for Clinical Decision
European Endocrinology. 2020;16(1):72-4
Catecholamine-secreting tumours that arise from chromaffin cells of the adrenal medulla and the sympathetic ganglia are respectively referred to as pheochromocytomas and paragangliomas. The term paraganglioma is also used for tumours derived from parasympathetic tissue in the head and neck, most of which do not produce catecholamines.1 The classic triad of symptoms in patients with […]
Diabetic Polyneuropathy – Advances in Diagnosis and Intervention Strategies
European Endocrinology. 2020;16(1):15–20
Diabetic polyneuropathy (DPN) is the most common microvascular complication of diabetes, affecting approximately 50% of all people with diabetes (type 1 diabetes [T1D] and type 2 diabetes [T2D]).1 DPN is a major cause of disability due to sensory loss, gait instability and fall‐related injuries,1–5 and is the strongest risk factor for diabetic foot ulceration and amputation.1–4 Up to […]
Cost Comparison of Flash Continuous Glucose Monitoring with Self-monitoring of Blood Glucose in Adults with Type 1 or Type 2 Diabetes Using Intensive Insulin—From a US Private Payer Perspective
US Endocrinology. 2020;16(1):24–30 DOI: https://doi.org/10.17925/USE.2020.16.1.24
Unmet needs for glucose monitoring in people with diabetes mellitus using intensive insulin Glucose monitoring is essential for people using intensive insulin to inform adjustments to the treatment and management of diabetes. Evidence suggests many people do not adhere to the recommended testing frequency with self-monitoring of blood glucose (SMBG). In the USA, it was […]